Vaccines for human papillomavirus infection and anogenital disease /
Saved in:
| Imprint: | Austin, Tex. : R.G. Landes, c1999. |
|---|---|
| Description: | 196 p. : ill. 24 cm. |
| Language: | English |
| Series: | Medical intelligence unit |
| Subject: | |
| Format: | E-Resource Print Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/3958828 |
Table of Contents:
- 1.. Immunomodulation of HPV Infection and Disease: An Overview
- Prospects for Vaccines for HPV: Theoretical Considerations
- Three Stages for Immune Intervention
- Delivery Systems: How Best to Deliver the Vaccines
- What the Animal Models Teach
- Strategies for Clinical trials: Who to Vaccinate? What is the Read-Out for Vaccine Efficacy?
- HPV Vaccines: Recent Developments
- Conclusions
- 2.. Immunobiology of HPV Infection
- HPV Infection
- Models of HPV Immunobiology
- Immune Response to HPV
- Future Directions
- 3.. HPV Vaccines for Protection Against Infection
- HPV-Associated Diseases
- HPV Proteins as Targets for Prophylactic Vaccination
- 4.. Vaccine for Genital Warts
- Development of TA-GW
- Preclinical Characterization of TA-GW
- Clinical Development
- Immunogenicity
- Clinical Efficacy
- Alternative Vaccine Strategies
- Future Development of TA-GW
- Summary
- 5.. Anti-Tumor Immunotherapy with Synthetic Peptides Representing Tumor-Associated T-Cell Epitopes: Implications for Peptide-Based Vaccination of Cervical Cancer
- Exploiting the Immune System for Treatment of Cancer
- HPV and Cervical Carcinoma
- Immune Surveillance Against HPV-Associated Cervical Carcinoma
- Vaccination Strategies in Animal Models
- Extrapolation to Humans: HLA Transgenic Mice and In Vitro Response Inductions
- Clinical trials
- 6.. Recombinant Vaccinia Virus
- Vaccinia Virus
- Human Papillomavirus
- Clinical trials
- Are Recombinant Vaccinia Virus-Based Vaccines the Ideal Vectors for HPV-Associated Cervical Disease?
- Use of Recombinant Viral Vectors to Investigate Role of Naturally Occurring HPV-Specific CTL in Cervical Neoplasia
- 7.. Safety and Immunogenicity of HPV16 E7/Algammulin
- Clinical Study Vaccination
- Assessment
- Results
- Discussion
- 8.. DNA Vaccines for Papillomavirus Infections
- The Three Waves of Vaccinology
- Nucleic Acid Vaccination
- Immunobiology of DNA Vaccination
- Variables that Affect Vaccine Efficacy
- Safety Concerns Regarding Nucleic Acid Vaccination
- Nucleic Acid Vaccines for Papillomavirus: Recent Progress
- Future Possibilities and Promising Advances
- Designer Vaccines for Papillomavirus Infections
- 9.. Experimental Vaccine Strategies for Cancer Immunotherapy
- Importance of Cell-Mediated Immune Responses in Controlling Both HPV Infections and HPV-Associated Neoplasms
- Manipulation of the Dendritic Cells Via Ex Vivo Methods
- Manipulation of the Dendritic Cells Via In Vivo Methods
- Vaccine Strategies Related to GM-CSF
- Vaccine Strategies Related to Flt3 Ligand
- Modification of Antigen Presentation Pathways for the Design of Cancer Vaccines
- Summary
- 10.. Live Recombinant Vaccine Vectors for HPV Antigens Associated with Infection and Malignancy
- Adenovirus
- An Introduction to Bacteria-Based HPV Vaccines
- Overview of Biological Properties and Infection Cycle of Bacterial Vectors
- Induction of Host Immunity to Virally-Derived Proteins and Tumor Antigens
